Kimberly Manhard - 30 May 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Role
Director
Signature
/s/ Kelly D. Deck, Chief Financial Officer of Inhibrx Biosciences, Inc., attorney-in-fact
Issuer symbol
INBX
Transactions as of
30 May 2024
Net transactions value
$0
Form type
4
Filing time
30 May 2024, 18:11:10 UTC
Previous filing
24 May 2024
Next filing
30 Aug 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INXB Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 30 May 2024 Common Stock 30,000 $15.86 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
F2 This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date.